Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
暂无分享,去创建一个
Deepak L. Bhatt | C. Reid | K. Eagle | M. Marre | R. Roussel | P. Steg | M. Ohman | U. Zeymer | L. Potier | Y. Elbez
[1] Deepak L. Bhatt,et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.
[2] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[3] Deepak L. Bhatt,et al. Advancing the care of cardiac patients using registry data: going where randomized clinical trials dare not. , 2010, JAMA.
[4] E. Boersma,et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients , 2012, European heart journal.
[5] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[6] Jeroen J. Bax,et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.
[7] Deepak L. Bhatt,et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. , 2014, European heart journal.
[8] M. Seguí Díaz,et al. [Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis]. , 2014, Semergen.
[9] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[10] K. Dickstein,et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.
[11] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.
[12] B. Lévy. Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin–Angiotensin System , 2003, Circulation.
[13] S. Bangalore,et al. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. , 2016, Mayo Clinic proceedings.
[14] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[15] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[16] S. Yusuf,et al. Telmisartan to prevent recurrent stroke and cardiovascular events. , 2008, The New England journal of medicine.
[17] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[18] J. Ménard,et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) , 2004, BMJ : British Medical Journal.
[19] B. Gersh,et al. ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology , 2013 .
[20] B. Gersh. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events , 2009 .
[21] Deepak L. Bhatt,et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. , 2012, JAMA.
[22] P. Ponikowski,et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.
[23] J. Mustonen,et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.
[24] Sankey V. Williams,et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.
[25] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[26] Deepak L. Bhatt,et al. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. , 2009, European heart journal.
[27] M. Pfeffer,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both , 2004 .
[28] K. Dickstein,et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.
[29] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[30] M. Tonelli,et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis , 2015, The Lancet.
[31] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[32] K. Rahimi,et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.
[33] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.
[34] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.